Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Clear Cell Renal Cell CarcinomaLocally Advanced Clear Cell Renal Cell CarcinomaLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
DRUG

Adavosertib

Given PO

Trial Locations (29)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

20007

MedStar Georgetown University Hospital, Washington D.C.

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

37204

Vanderbilt Breast Center at One Hundred Oaks, Nashville

37232

Vanderbilt University/Ingram Cancer Center, Nashville

48201

Wayne State University/Karmanos Cancer Institute, Detroit

48334

Weisberg Cancer Treatment Center, Farmington Hills

60451

UC Comprehensive Cancer Center at Silver Cross, New Lenox

60462

University of Chicago Medicine-Orland Park, Orland Park

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

63129

Siteman Cancer Center-South County, St Louis

63136

Siteman Cancer Center at Christian Hospital, St Louis

63141

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

66160

University of Kansas Cancer Center, Kansas City

66205

University of Kansas Clinical Research Center, Fairway

University of Kansas Hospital-Westwood Cancer Center, Westwood

77030

M D Anderson Cancer Center, Houston

92868

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

94115

UCSF Medical Center-Mount Zion, San Francisco

94158

UCSF Medical Center-Mission Bay, San Francisco

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT03284385 - Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 | Biotech Hunter | Biotech Hunter